# IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Source: https://onco.cc/trials/nct06030258/  
OnCo record `nct06030258` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IN10018, Tislelizumab, Carboplatin in small-cell lung cancer, run by InxMed (Shanghai) Co., Ltd., now recruiting.

## Summary

IN10018 Combination Therapy in Treatment-naïve ES-SCLC is a phase 1/2 interventional study registered as NCT06030258 by InxMed (Shanghai) Co., Ltd., with 120 participants planned, started 2023-10-30 and due to reach its primary completion in 2025-12-24. Interventions recorded: IN10018, Tislelizumab, Carboplatin, Etoposide. Conditions listed: Small Cell Lung Cancer Extensive Stage. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06030258
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Trial to Evaluate the Anti-tumor Efficacy, Safety, Tolerability, and Pharmacokinetics of IN10018 Combined With Anti-PD-1/L1 Antibody and Chemotherapy as First-line Treatment in Extensive-stage Small Cell Lung Cancer
- Sponsor: InxMed (Shanghai) Co., Ltd.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06030258: https://clinicaltrials.gov/study/NCT06030258

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Etoposide](https://onco.cc/drugs/etoposide/), [IN10018](https://onco.cc/drugs/in10018/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [InxMed (Shanghai)](https://onco.cc/companies/inxmed-shanghai/)

---
JSON: https://onco.cc/api/v1/entities/nct06030258.json